Prognostic value of the prognostic immune-inflammatory-nutritional score in patients with advanced gastric cancer treated with immunochemotherapy

Table 2 Comparison of features between the training and validation sets, n (%)

Variables	Total (n = 200)	Test (n = 60)	Train (n = 140)	χ2	P value
Gender				0.63	0.426
Female	75 (37.50)	20 (33.33)	55 (39.29)
Male	125 (62.50)	40 (66.67)	85 (60.71)
Age (years)				3.14	0.076
< 60 years	78 (39.00)	29 (48.33)	49 (35.00)
≥ 60 years	122 (61.00)	31 (51.67)	91 (65.00)
BMI (kg/m2)				0.55	0.46
< 25	166 (83.00)	48 (80.00)	118 (84.29)
≥ 25	34 (17.00)	12 (20.00)	22 (15.71)
CEA (ng/mL)				0.17	0.682
≥ 3	121 (60.50)	35 (58.33)	86 (61.43)
< 3	79 (39.50)	25 (41.67)	54 (38.57)
CA199 (ng/mL)				0.08	0.773
< 37	127 (63.50)	39 (65.00)	88 (62.86)
≥ 37	73 (36.50)	21 (35.00)	52 (37.14)
PIIN score				0.72	0.397
Low	68 (34.00)	23 (38.33)	45 (32.14)
High	132 (66.00)	37 (61.67)	95 (67.86)
ECOG				0.76	0.384
0	71 (35.50)	24 (40.00)	47 (33.57)
1	129 (64.50)	36 (60.00)	93 (66.43)
TNM staging				0.16	0.686
III	89 (44.50)	28 (46.67)	61 (43.57)
IV	111 (55.50)	32 (53.33)	79 (56.43)
Peritoneal metastasis				0	0.975
No	113 (56.50)	34 (56.67)	79 (56.43)
Yes	87 (43.50)	26 (43.33)	61 (43.57)
Liver metastasis				2.15	0.143
No	157 (78.50)	51 (85.00)	106 (75.71)
Yes	43 (21.50)	9 (15.00)	34 (24.29)
PD-L1 expression				0.19	0.663
CPS < 5	88 (44.00)	25 (41.67)	63 (45.00)
CPS ≥ 5	112 (56.00)	35 (58.33)	77 (55.00)
MMR status				0.28	0.596
pMMR	158 (79.00)	46 (76.67)	112 (80.00)
dMMR	42 (21.00)	14 (23.33)	28 (20.00)

BMI: Body mass index; CEA: Carcinoembryonic-antigen; CA199: Carbohydrate antigen 199; PIIN: Prognostic immune-inflammatory-nutritional; ECOG: Eastern Cooperative Oncology Group; PD-L1: Programmed death-ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.